Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antiviral Research

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.ANTIVIRAL.2007.10.014PMID 18078676
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Hepatitis B

  2007cited by this paper
• Hepatitis B today.

  2007cited by this paper
• Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

  2006cited by this paper
• Hepatitis B virus genotype B is associated with better response to thymosin α1 therapy than genotype C

  2006cited by this paper
• A Randomized, Controlled, Clinical Study of Thymosin Alpha‐1 Versus Interferon‐Alpha in Chinese Patients with Chronic Hepatitis B Lacking Hepatitis B Envelope Antigen

  2005cited by this paper
• A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].

  2005cited by this paper
• The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial

  2005cited by this paper
• Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma.

  2003cited by this paper
• Therapy of chronic hepatitis B: current challenges and opportunities

  2002cited by this paper
• Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B.

  2002cited by this paper
• Thymosin-α1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B

  2002cited by this paper
• Preliminary results of Thymosin-a1 vs interferon-α treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B

  2001cited by this paper
• Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

  2001cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

  2001cited by this paper
• Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.

  2001cited by this paper
• Thymosin alpha-1.

  2001cited by this paper
• Systematic reviews in health care: Assessing the quality of controlled clinical trials.

  2001cited by this paper
• A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

  2001cited by this paper
• The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta‐analysis

  2001cited by this paper
• Randomized controlled clinical trial on the treatment of Thymosin-a1 vs interferon-α in patients with hepatitis B

  2001cited by this paper
• Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2001cited by this paper
• A Randomized, Controlled Study of Thymosin-α1 Therapy in Patients with Anti-HBe, HBV-DNA-Positive Chronic Hepatitis B

  2000cited by this paper
• A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.

  2000cited by this paper
• Publication bias in meta-analysis: its causes and consequences.

  2000cited by this paper
• Thymosin‐α1 regulates MHC class I expression in FRTL‐5 cells at transcriptional level

  2000cited by this paper
• Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.

  1999cited by this paper
• Thymosin α1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double‐blind and placebo‐controlled study

  1999cited by this paper
• Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial

  1998cited by this paper
• Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.

  1998cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.

  1996cited by this paper
• A randomized controlled trial of thymosin‐α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B

  1996cited by this paper
• Thymosin treatment of chronic hepatitis B: A placebo‐controlled pilot trial

  1991cited by this paper
• Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones.

  1987cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

  1986cited by this paper

• Thymosin-ɑ1 for people with chronic hepatitis B

  2022cites this paper
• Compilation of antiviral treatments and strategies to fight fish viruses

  2020cites this paper
• Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo

  2020cites this paper
• The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy.

  2019cites this paper
• Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines.

  2019cites this paper
• Immunomodulatory and enhanced antitumor activity of a modified thymosin &agr;1 in melanoma and lung cancer

  2018cites this paper
• Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo.

  2018cites this paper
• Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

  2018cites this paper
• REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.

  2018cites this paper
• Effect of a C-end rule modification on antitumor activity of thymosin α1.

  2018cites this paper
• Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study

  2018cites this paper
• Immune therapy for hepatitis B.

  2016cites this paper
• Thymosin alpha-1 treatment in chronic hepatitis B

  2015cites this paper
• Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.

  2015cites this paper
• Historical review of thymosin α 1 in infectious diseases

  2015influential citation
• Chronic hepatitis B: A wave of new therapies on the horizon.

  2015cites this paper
• Análisis de las bases moleculares de la resistencia a la quimioterapia y estrategias para su optimización: rol de las proteínas ABC, la apoptosis y la transformación celular

  2015cites this paper
• Emerging antivirals for the treatment of hepatitis B.

  2014cites this paper
• Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)

  2014cites this paper
• Designing immune therapy for chronic hepatitis B.

  2014cites this paper
• Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides

  2013cites this paper
• Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.

  2013cites this paper
• Generation of Mature Nα-Terminal Acetylated Thymosin α1 by Cleavage of Recombinant Prothymosin α

  2013cites this paper
• Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation

  2013cites this paper
• Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications

  2013cites this paper
• Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

  2012cites this paper
• Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review

  2011cites this paper
• Emerging pipeline drugs for hepatitis B infection

  2011cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].

  2011cites this paper
• Treatment optimization of HBeAg-negative chronic viral hepatitis B with thymosin-α1

  2010cites this paper
• In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.

  2010cites this paper
• Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection

  2010cites this paper
• Current treatment of chronic HBV infection: An Asian-Pacific perspective

  2009influential citation
• Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein.

  2008cites this paper